# Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

> **NCT02447679** · PHASE2 · COMPLETED · sponsor: **Chang Gung Memorial Hospital** · enrollment: 40 (actual)

## Conditions studied

- Adult Hepatocellular Carcinoma
- Recurrent Hepatocellular Carcinoma
- Adverse Reaction to Drug
- Vascular Endothelial Growth Factor Overexpression

## Interventions

- **DRUG:** thalidomine
- **DRUG:** tegafur-uracil

## Key facts

- **NCT ID:** NCT02447679
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2017-01-31
- **Final completion:** 2017-02-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02447679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02447679, "Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02447679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*